Video Experimental Relacionado
Updated: May 11, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Inmunoensambladores de células T bispecíficos para enfermedades autoinmunes del tejido conectivo refractarias al
Christina Düsing1,2,3, Andrea-Hermina Györfi1,2,3, Ayla Nadja Stütz1,2
1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany.
Nature medicine
|February 19, 2026
Resumen
El blinatumomab y el teclistamab muestran promesa como terapias de rescate para el síndrome antisintetasa (AsyS) y la esclerosis sistémica (ES) graves. Estos inmunoensambladores de células T (TCE) mejoraron los síntomas y redujeron los autoanticuerpos en pacientes refractarios al tratamiento.
Área de la Ciencia:
- Inmunología; Reumatología; Oncología
Sus antecedentes:
- El síndrome antisintetasa (AsyS) y la esclerosis sistémica (ES) son enfermedades autoinmunes con necesidades médicas insatisfechas significativas.; Los casos refractarios al tratamiento plantean desafíos, lo que requiere estrategias terapéuticas novedosas.
Objetivo del estudio:
- Evaluar la eficacia y seguridad del blinatumomab y el teclistamab como terapias de uso compasivo para AsyS y ES refractarias al tratamiento, respectivamente.; Evaluar el impacto de estos inmunoensambladores de células T (TCE) en los marcadores de la enfermedad, los resultados clínicos y los eventos adversos.
Principales métodos:
- Cinco pacientes con AsyS refractaria al tratamiento recibieron blinatumomab (TCE CD19×CD3).; Cinco pacientes con ES refractaria al tratamiento recibieron teclistamab (TCE BCMA×CD3).; Se utilizó terapia de mantenimiento con rituximab (RTX) para inhibir la rediferenciación de células B.
Principales resultados:
- El blinatumomab mejoró la miositis y estabilizó la enfermedad pulmonar intersticial (EPI) en pacientes con AsyS, reduciendo las células diana y los autoanticuerpos.; El teclistamab mejoró la fibrosis cutánea, estabilizó la EPI y resolvió los roces tendinosos en pacientes con ES.; Se logró un control prolongado de la enfermedad con mantenimiento de RTX, incluso en pacientes no respondedores a RTX. Los eventos adversos incluyeron síndrome de liberación de citoquinas (SRC) e infecciones respiratorias.
Conclusiones:
- El blinatumomab y el teclistamab demuestran potencial como terapias de rescate para AsyS y ES refractarias.; Estos TCE pueden inducir mejoras clínicas, serológicas e histológicas.; Se justifica una mayor investigación para establecer su papel en el manejo de estas complejas enfermedades autoinmunes.
Palabras clave:
inmunoensambladores de células T bispecíficossíndrome antisintetasaesclerosis sistémicaterapia de rescateautoinmunidadMás Videos Relacionados
Videos de Conceptos Relacionados
01:40Cell-mediated Immune Responses
Overview
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...